Associate Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. Tom R. Fitch, MD
|
|
Give Review
Fitch is an expert in the field of Hematology. He attended University of Kansas School of Medicine. He has 5 awards "America's Top Doctors", "Top Doctors:Arizona State", "America's Top Doctors for Cancer", "Super Doctor" and "Top MD". Fitch is also a published MD. He has 37 publication published. The most recent publication is: Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consor... He is registered with Medicare.
Publications
- Safety and activity of temsirolimus and bevacizumab in patients with advanced Renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consor...
- The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast Cancer, N00C9.
- Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer.
- Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities.
- Hepatic Arterial Infusion and Systemic Chemotherapy After Multiple Metastasectomy in Patients With ColoRectal Carcinoma Metastatic to the Liver: A North Central Cancer...
- A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
- Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial.
- Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal Cancer and gastroesophageal junction tumors.
- Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory Cancers.
- A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a north central Cancer treatment group study, N057E1.
- A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patie...
- Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced coloRectal carcinoma previously treated wi...
- A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).
- Phase II trial of sorafenib in patients with metastatic breast Cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Cl...
- Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study...
- A placebo-controlled double blind trial of etanercept for the Cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
- Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
- Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung Cancer.
- Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
- Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.
- Low-molecular-weight heparin in patients with advanced Cancer: a phase 3 clinical trial.
- Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.
- Metastatic Prostate carcinoma mimicking meningioma: case report and review of the literature.
- Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine.
- Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central...
- Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
- Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938...
- Randomized phase II study of two irinotecan schedules for patients with metastatic breast Cancer refractory to an anthracycline, a taxane, or both.
- Decision-making role preferences of patients receiving adjuvant Cancer treatment: a university of Rochester Cancer center community clinical oncology program.
- A phase II study of the dolastatin 15 Analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.
- Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Can...
- A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic Cancer.
- A phase II trial of green tea in the treatment of patients with androgen independent metastatic Prostate carcinoma.
- Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic coloRectal carcinoma.
- Phase II trial of KW2189 in patients with advanced Malignant melanoma.
- Dronabinol versus megestrol acetate versus combination therapy for Cancer-associated anorexia: a North Central Cancer Treatment Group study.
Schools
University of Kansas School of Medicine
University Of Michigan
Mayo Clinic Rochester
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:Arizona State
- America's Top Doctors for Cancer
- Super Doctor
- Top MD
Education
-
Mayo School of Graduate Medical Education -
University of Michigan Hospitals and Health Centers -
University of Kansas School of Medicine
Hospital
-
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
| NPI NUMBER | 1205812294 | |
| NPPES Provider LastName | FITCH | |
| NPPES Provider FirstName | TOM | |
| NPPES Provider ZIPCode | 852595404 | |
| NPPES Provider State | AZ | |
| Specialty Description | Hospice and Palliative Care | |
| Total Claim Count | 312.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 81.0 | |
| Percent Opioid Claims | 25.96 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205812294 |
| Last Name Of The Provider | FITCH |
| First Name Of The Provider | TOM |
| View All |
Similar Doctors
|
Dr. Irwin L. Levey, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adrienne D. Briggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mitesh J. Borad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald W. Northfelt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric E. Prommer, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Riccardo Valdez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chad C. Cherington, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James O. Newell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Joanne L. Schlesinger, NP |